

제 9 장

호르몬 제제 및 호르몬요법의 유형

1. Akrivis C, Varras M, Thodos A, Hadjopoulos G, Bellou A, Antonious N, Action of 25 microg 17beta-oestradiol vaginal tablets in the treatment of vaginal atrophy in Greek postmenopausal women: clinical study, *Clin Exp Obstet Gynecol* 2003; 30: 229-34.
2. Al-Azzawi F, Buckler HM, United Kingdom Vaginal Ring Investigator Group, Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms, *Climacteric* 2003; 6: 119-27.
3. Allison MA, Manson JE. Observational studies and clinical trials of menopausal hormone therapy: can they both be right? *Menopause* 2006; 13: 1-3.
4. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA* 2004; 291: 1701-12.
5. Archer DF, EstroGel Study Group. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women. *Menopause* 2003; 10: 494-6.
6. Burger HG. Hormonotherapy in the WHI era. *Aust N Z J Obstet Gynaecol* 2006; 46: 84-91.
7. Gill S. Discontinuation of menopausal hormone therapy: what are the symptoms and how should they be managed? *Nat Clin Pract Endocrinol Metab.* 2006; 2: 192-3.
8. Hossain M, Quebe-Fehling E, Sergejew T, Schmidt G, Comparative bioequivalence studies with Estradot and Menorest transdermal systems. *Maturitas* 2003; 46: 187-198
9. Lobo RA. Treatment of the postmenopausal women. 2nd ed. Lippincott Williams & Wilkins Press; . 1999. p.95.
10. Porch JV, Lee IM, Cook NR, Rexrode KM, Burin JE, Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). *Cancer Causes Contr* 2002; 13: 847-54.
11. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M, Ultralow-dose micronized 17betaestradiol and bone density and bone metabolism in older women: a randomized

- controlled trial. *JAMA* 2003; 290: 1042-8.
12. Richman S, Edusa V, Fadiel A, Naftolin F. Low-dose estrogen therapy for prevention of osteoporosis: working our way back to monotherapy. *Menopause* 2006; 13: 149-55.
 13. Roy S, Caillouette JC, Roy T, Faden JS. Vaginal pH is similar to FSH for menopause diagnosis. *Am J Obstet Gynecol* 2004; 190: 1272-7.
 14. Savvas M, Studd JW, Fogelman I, Dooley M, Montgomery J, Murby B. Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women. *BMJ* 1988; 297: 331-3.
 15. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. *N Engl J Med* 2001; 345: 1243-9.
 16. Weiderpass E, Baron JA, Adami HO, Magnusson C, Lindgren A, Bergstrom R et al. Lowpotency oestrogen and risk of endometrial cancer: a case-control study. *Lancet* 1999; 353: 1824-8.
 17. Archer DF. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. *Menopause* 2001; 8: 245-51.
 18. Archer DF, Dorin M, Lewis V, Schneider DL, Picker JH. Effects of lower doses of conjugated and medroxyprogesterone acetate on endometrial bleeding. *Fertil Steril* 2001; 1080: 75-8.
 19. Boggs P, Utian W. The North American Menopause Society develops consensus opinions. *Menopause* 1998; 5: 67-68.
 20. King RJ, Whitehead MI. Assessment of the potency of orally administered progestins in women. *Fertil Steril* 1986; 46: 1062-66.
 21. North American Menopause Society. Role of progestogen in hormone therapy for postmenopausal women. position statement of The North American Menopause Society. *Menopause* 2003; 10: 113-32.
 22. Shau WY, Hsieh CC, Hsieh TT, Hung TH, Huang KE. Factors associated with endometrial bleeding in continuous hormone replacement therapy. *Menopause* 2002; 9: 189-94.
 23. Wegienka G, Havstad S, Kelsey JL. Menopausal hormone therapy in a health maintenance organization before and after women's health initiative hormone trials termination. *J Womens Health* 2006; 15: 369-78.
 24. Wildemeersch D, Schacht E, Wildemeersch P. Performance and acceptability of intrauterine release of levonorgestrel with a miniature delivery system for hormonal substitution therapy, contraception and treatment in peri and postmenopausal women. *Maturitas* 2003; 44: 237-45.

25. Archer DF, Furst K, Tipping D, Dain MP, Vandepol C. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. *Combi Patch Study Group. Obstet Gynecol* 1999; 94: 499-503.
26. Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxy progesterone acetate. *Menopause Study Group. Obstet Gynecol* 1994; 83: 686-92.
27. Grubb G, Spielmann D, Pickar J, Constantine G. Clinical experience with trimegestone as a new progestin in HRT. *Steroids* 2003; 68: 921-6.
28. Rubinacci A, Peruzzi E, Modena AB, Zanardi E, Andrei B, De Leo V, et al. Effects of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women. *Menopause* 2003; 10: 241-9.
29. Vereide AB, Arnes M, Straume B, Maltau JM, Orbo A. Nuclear morpho-meric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonogestrel and systemic medroxyprogesterone. *Gynecol Oncol* 2003; 91: 526-33.
30. Wells M, Sturdee D, Barlow DH, Ulrich LG, O'Brien K, Campbell MJ, et al. Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study. *Br Med J* 2002; 325: 239-43.
31. Montplaisier J, Lorrain J, Denesle R, Petit D. Sleep in menopause: differential effects of two forms of hormone replacement therapy. *Menopause* 2001; 8: 10-3.
32. Notelovitz M, Cassel D, Hille D, Furst KW, Dain MP, VandePol C, et al. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause. *Am J Obstet Gynecol* 2000; 182: 7-10.
33. Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. *BMJ* 1989; 298: 147-51.
34. Rowan JP, Simon JA, Speroff L, Ellman H. Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials. *Clin Ther.* 2006; 28: 921-32.
35. Shulman LP, Yankov V, Uhl K. Safety and efficacy of a continuous once-a-week 17betaestradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multi-center, double-blind, randomized controlled trials, *Menopause* 2002; 9: 195-9.

36. Speroff L, Symons J, Kempfert N, Rowan J, for the Study Investigators. The effect of varying low-dose combinations of norethindrone acetate and etinyl estradiol on the frequency and intensity of vaso-motor symptoms. *Menopause* 2000; 7: 383-9.
37. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. *Fertil Steril* 2001; 75: 1065-71.
38. Archer DF, Hendrix S, Ferenczy A, Felix J, Gallagher JC, Rymer J, et al. Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women. *Fertil Steril* 2007; 88: 866-878.
39. Cummings SR. LIFT study is discontinued. *BMJ* 2006; 332: 667.
40. Cummings SR, Bilezikian JP, Christiansen C, Eastell R, Ettinger B, Delmas P, et al. The effects of tibolone in older women : Results of the LIFT trial. 34th European symposium on calcified tissue. Copenhagen, Denmark, 2007 5-9, May.
41. Hammar M, Christau S, Nathorst-Böös J, Rud T, Garre K. A double-blind, randomized trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. *Br J Obstet Gynaecol* 1998; 105: 904-911.
42. Helmond FA, Kloosterboer HJ. Safety and tolerability of Livial. In: Genazzani AR, editor. *Hormone Replacement Therapy Cancer. The Current Status of Research and Practice* Boca Raton: The Parthenon Publishing Group Press; 2002. p.252-256.
43. Huber J, Palacios S, Berglund L, Hänggi W, Sathanandan SM, Christau S. Effect of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women *BJOG* 2002; 109: 886-893.
44. Langer RD, Landgren BM, Rymer J, Helmond FA. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study. *Am J Obstet Gynecol* 2006; 195: 1320-7.
45. Landgren MB, Bennink HJ, Helmond FA, Engelen S. Dose-response analysis of effects of tibolone on climacteric symptoms. *BJOG* 2002; 109: 1109-1114.
46. Rymer J, Robinson J, Fogelman I. Ten years of treatment with tibolone 2.5mg daily: effects on bone in postmenopausal women. *Climacteric* 2002; 5: 390-398.
47. Taskin O, Yalcinoglu AI, Kucuk S, Uryan I, Buhur A, Burak F. Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis. *Fertil Steril* 1997; 67: 40-45.
48. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper J. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-bind-

- ing globulin levels through the menopause transition, *J Clin Endocrinol Metab* 2000; 85: 2832-8.
49. Buckler HM, Robertson WR, Wu FCW. Which androgen replacement therapy for women? *J Clin Endocrinol Metab* 1998; 83: 3920-4.
 50. Barrett-Connor E, Timmons C, Young R, Witta B, and the Estratest Working Group. Interim safety analysis of a two-year study comparing oral estrogen-androgen and conjugated estrogens in surgically menopausal women. *J Womens Health* 1996; 5: 593-602.
 51. Bachmann GA, Timmons MC, Abernethy WD. Breakthrough bleeding patterns in two continuous combined estrogen/progestogen hormone replacement therapies, one of which included androgens. *J Womens Health Gend Based Med* 1996; 5: 205-12.
 52. Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, et al. Testosterone for low libido in postmenopausal women not taking estrogen, *New Engl J Med* 2008; 359: 2005-17.
 53. Davis SR, McCloud P, Strauss BJG, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. *Maturitas* 1995; 21: 227-36.
 54. Fritz MA, Speroff L. *Clinical gynecologic endocrinology and infertility*. 8th ed. New York: Lippincott Williams & Wilkins 2010; p.763-5.
 55. Garnett T, Studd J, Watson N, Savvas M, Leather A. The effects of plasma estradiol levels on increases in vertebral and femoral bone density following therapy with estradiol and estradiol with testosterone implants. *Obstet Gynecol* 1992; 79: 969-72.
 56. Hameed A, Brothwood T, Bouloux P. Delivery of testosterone replacement therapy. *Curr Opin Investig Drugs* 2003; 4: 1213-9.
 57. Hickok LR, Toomey C, Speroff L. A comparison of esterified estrogens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in postmenopausal women. *Obstet Gynecol* 1993; 82: 919-24.
 58. Hofing M, Hirschberg AL, Skoog L, Tani E, Hagerstrom T, von Schoultz B. Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. *Menopause* 2007; 14: 183-90.
 59. Jiroutek MR, Chen M-H, Johnston CC, Longcope C. Changes in reproductive hormones and sex hormone-binding globulin in a group of postmenopausal women measured over 10 years. *Menopause* 1998; 5: 90-4.
 60. Labrie F, Belanger A, Cusan L, Gomez J-L, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. *J Clin Endocrinol Metab* 1997; 82: 2396-402.
 61. Myers LS, Dixen J, Morrissette D, Carmichael M, Davidson JM. Effects of estrogen, androgen, and progestin on sexual psychophysiology and behavior in postmenopausal

- women. *J Clin Endocrinol Metab* 1990; 70: 1124-31.
62. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. *Psychosom Med* 1987; 49: 397-409.
 63. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. *New Eng J Med* 2000; 343: 682-8.
 64. Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. *Arch Intern Med* 2006;166: 1483-9.
 65. Urman B, Pride SM, Ho Yuen B. Elevated serum testosterone, hirsutism, and virilism associated with combined androgenestrogen hormone replacement therapy. *Obstet Gynecol* 1991; 77: 595-8.
 66. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgens on bone mineral density, menopausal symptoms, and lipid-lipo-protein profiles in surgical menopause. *Obstet Gynecol* 1995; 85: 529-37.
 67. 대한골대사학회. 골다공증. 제 4판. 서울. 군자출판사; 2012. p.330-331.